AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
Lung cancer has a high mortality rate, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients have been observed to acquire resistance against various anticancer agents used for NSCLC due to L858R (or Exon del19)/T790M/C797S-EGFR mutations. Therefore, next-generation...
Main Authors: | Geunho Choi, Daegeun Kim, Junehwan Oh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.660313/full |
Similar Items
-
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01) -
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01) -
ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study
by: Min Chen, et al.
Published: (2021-10-01) -
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01)